Compass Therapeutics Stock Downgraded and Upheld by Analysts Amid Trial Results
On Monday morning, **Raymond James (NYSE: RJF)** downgraded **Compass Therapeutics (NASDAQ: CMPX)** from “Strong Buy” to “Market Perform” after the biotech firm’s Phase 2 trial of tovecimig in bile duct ... Read More